IPO registrations (S-1, F-1) · Registrants
CervoMed Inc.
- SEC CIK
- 1053691 · filings on EDGAR ↗
- Former names
- Diffusion Pharmaceuticals Inc. (2016–2023); RestorGenex Corp (2014–2016); Stratus Media Group, Inc (2008–2014); FERIS INTERNATIONAL, INC. (2008–2008); TITAN MOTORCYCLE CO OF AMERICA INC (1998–2008)
- Registration
- Form S-1, first filed 2011-08-12, last 2024-05-30; 8 initial registrations, 10 amendments
- Outcome
- Final prospectus filed 2018-01-19; declared effective 2012-02-13
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- 20 PARK PLAZA, SUITE 424, Boston, MA 02116
- EIN
- 30-0645032
- Ticker
- CRVO (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- CervoMed Inc. on the corporate pages
Offering terms
- Final price
- $0.80 per share (424B4 filed 2018-01-19)
- Shares sold
- 15,000,000
- Gross proceeds
- $12,000,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol DFFN
- Lead underwriters
- H.C. Wainwright
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Form 5500 plan sponsor: RESTORGENEX CORPORATION EXACT (EIN (EXACT))
- Form D issuer: Diffusion Pharmaceuticals Inc. EXACT (CIK (EXACT))
- SEC filer: CervoMed Inc. EXACT (CIK (EXACT))
- Person page: Jane H Hollingsworth Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
Filings 36
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2011-08-12 | S-1 | S-1 (registration) | Stratus Media Group, Inc | 0001157523-11-005009 ↗ |
| 2011-09-22 | S-1/A | S-1/A (amendment) | Stratus Media Group, Inc | 0001157523-11-005478 ↗ |
| 2012-02-10 | S-1/A | S-1/A (amendment) | Stratus Media Group, Inc | 0001157523-12-000675 ↗ |
| 2012-02-13 | S-1/A | S-1/A (amendment) | Stratus Media Group, Inc | 0001019687-12-000487 ↗ |
| 2012-02-13 | EFFECT | EFFECT (declared effective) | Stratus Media Group, Inc | 9999999995-12-000468 ↗ |
| 2014-07-14 | S-1 | S-1 (registration) | RestorGenex Corp | 0001019687-14-002726 ↗ |
| 2014-07-31 | EFFECT | EFFECT (declared effective) | RestorGenex Corp | 9999999995-14-002345 ↗ |
| 2016-01-11 | EFFECT | EFFECT (declared effective) | RestorGenex Corp | 9999999995-16-003496 ↗ |
| 2017-06-01 | EFFECT | EFFECT (declared effective) | Diffusion Pharmaceuticals Inc. | 9999999995-17-001429 ↗ |
| 2017-12-20 | S-1 | S-1 (registration) | Diffusion Pharmaceuticals Inc. | 0001437749-17-020965 ↗ |
| 2018-01-16 | S-1/A | S-1/A (amendment) | Diffusion Pharmaceuticals Inc. | 0001437749-18-000686 ↗ |
| 2018-01-17 | EFFECT | EFFECT (declared effective) | Diffusion Pharmaceuticals Inc. | 9999999995-18-000143 ↗ |
| 2018-01-19 | 424B4 | 424B4 (final prospectus) | Diffusion Pharmaceuticals Inc. | 0001437749-18-000841 ↗ |
| 2018-02-13 | EFFECT | EFFECT (declared effective) | Diffusion Pharmaceuticals Inc. | 9999999995-18-000437 ↗ |
| 2019-05-22 | EFFECT | EFFECT (declared effective) | Diffusion Pharmaceuticals Inc. | 9999999995-19-001185 ↗ |
| 2019-09-09 | S-1 | S-1 (registration) | Diffusion Pharmaceuticals Inc. | 0001437749-19-018077 ↗ |
| 2019-09-27 | S-1/A | S-1/A (amendment) | Diffusion Pharmaceuticals Inc. | 0001437749-19-019129 ↗ |
| 2019-10-08 | EFFECT | EFFECT (declared effective) | Diffusion Pharmaceuticals Inc. | 9999999995-19-002273 ↗ |
| 2019-10-16 | S-1 | S-1 (registration) | Diffusion Pharmaceuticals Inc. | 0001437749-19-020133 ↗ |
| 2019-10-28 | S-1/A | S-1/A (amendment) | Diffusion Pharmaceuticals Inc. | 0001437749-19-020753 ↗ |
| 2019-11-08 | S-1/A | S-1/A (amendment) | Diffusion Pharmaceuticals Inc. | 0001437749-19-022192 ↗ |
| 2019-11-13 | S-1/A | S-1/A (amendment) | Diffusion Pharmaceuticals Inc. | 0001437749-19-022543 ↗ |
| 2019-11-13 | EFFECT | EFFECT (declared effective) | Diffusion Pharmaceuticals Inc. | 9999999995-19-002563 ↗ |
| 2019-11-15 | 424B4 | 424B4 (final prospectus) | Diffusion Pharmaceuticals Inc. | 0001437749-19-022972 ↗ |
| 2019-12-20 | S-1 | S-1 (registration) | Diffusion Pharmaceuticals Inc. | 0001437749-19-024737 ↗ |
| 2019-12-27 | EFFECT | EFFECT (declared effective) | Diffusion Pharmaceuticals Inc. | 9999999995-19-002944 ↗ |
| 2020-05-29 | S-1 | S-1 (registration) | Diffusion Pharmaceuticals Inc. | 0001437749-20-012079 ↗ |
| 2020-06-03 | S-1/A | S-1/A (amendment) | Diffusion Pharmaceuticals Inc. | 0001437749-20-012354 ↗ |
| 2020-06-05 | EFFECT | EFFECT (declared effective) | Diffusion Pharmaceuticals Inc. | 9999999995-20-001389 ↗ |
| 2020-10-02 | EFFECT | EFFECT (declared effective) | Diffusion Pharmaceuticals Inc. | 9999999995-20-002734 ↗ |
| 2023-07-13 | EFFECT | EFFECT (declared effective) | Diffusion Pharmaceuticals Inc. | 9999999995-23-002078 ↗ |
| 2024-05-10 | S-1 | S-1 (registration) | CervoMed Inc. | 0001437749-24-016060 ↗ |
| 2024-05-30 | S-1/A | S-1/A (amendment) | CervoMed Inc. | 0001437749-24-018760 ↗ |
| 2024-06-05 | EFFECT | EFFECT (declared effective) | CervoMed Inc. | 9999999995-24-001754 ↗ |
| 2024-10-09 | EFFECT | EFFECT (declared effective) | CervoMed Inc. | 9999999995-24-003138 ↗ |
| 2024-10-10 | EFFECT | EFFECT (declared effective) | CervoMed Inc. | 9999999995-24-003159 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2018-01-16 | S-1/A | registration statement | 9,154,930 | - | Nasdaq DFFN | 1 | primary document; shares headline | document ↗ | ||
| 2018-01-19 | 424B4 | final prospectus | $0.80 | 15,000,000 | $12,000,000 | Nasdaq DFFN | 1 | primary document; price sentence, shares headline, proceeds table | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Feller Paul | Director,Officer,TenPercentOwner | Chief Exec.Officer & Chairman; Chief Executive Officer | 2 | 2008–2010 | |
| Feller Ralph | TenPercentOwner | 1 | 2008 | ||
| GOLENBERG GLENN | Director | 1 | 2009 | ||
| Cross Randall | Director | 1 | 2009 | ||
| Dunleavy Mike Sr. | Director | 1 | 2009 | ||
| BLECH ISAAC | Director; TenPercentOwner | 6 | 2011–2016 | ||
| Blech Miriam | TenPercentOwner | 1 | 2011 | ||
| Liberty Charitable Remainder Trust f/b/o Isaac Blech | TenPercentOwner | 2 | 2011–2013 | ||
| West Charitable Remainder Unitrust | TenPercentOwner | 2 | 2011–2013 | ||
| RUBINSTEIN JEROLD H | Director | 1 | 2011 | ||
| BEARCHELL CHARLES R | Officer | Chief Accounting Officer | 1 | 2011 | |
| SIEGEL SEYMOUR | Director | 1 | 2012 | ||
| Schneider John | Director | 1 | 2012 | ||
| River Charitable Remainder Unitrust f/b/o Isaac Blech | TenPercentOwner | 1 | 2013 | ||
| BARER SOL J | Director; Director,Officer,TenPercentOwner | Chairman of the Board | 4 | 2013–2014 | |
| Abolin Craig | Officer | VP of Research Canterbury Labs; VP of Research & Dev - Subsid. | 2 | 2013–2014 | |
| Schwartz Yael | Director,Officer; Director,Officer,TenPercentOwner | Exe. VP Preclinical Dev.; President, Canterbury Labs.; President of Subsidiaries | 3 | 2013–2014 | |
| STACKS NELSON K. | Director | 2 | 2013–2014 | ||
| Bright Rex | Director | 3 | 2014 | ||
| SIMES STEPHEN M | Director,Officer | Chief Executive Officer | 3 | 2014 | |
| SHERRIS DAVID | Director,Officer | Chief Scientific Officer; Chief Scientif Off & Div Pres; CSO & President of Division | 3 | 2014 | |
| DONENBERG PHILIP B | Director; Officer | Chief Financial Officer | 3 | 2014 | |
| Boris Timothy | Director; Officer | VP Legal Affairs & Secretary | 2 | 2014 | |
| Weinberg Mark A. | Officer | Sr. V.P.- Clinical Development; Sr.V.P.- Clinical Development | 2 | 2014 | |
| Adams Robert W | Director | 12 | 2016–2021 | ||
| Byrne Thomas E | Director; Officer | General Counsel | 8 | 2016–2020 | |
| Gainer John | Director,Officer | Chief Scientific Officer | 9 | 2016–2020 | |
| Giles Mark T | Director | 14 | 2016–2021 | ||
| LEVIN ALAN G | Director | 12 | 2016–2021 | ||
| Kalergis David G | Director,Officer | Chairman and CEO | 9 | 2016–2020 | |
| Jones David Randolph | Officer | Chief Medical Officer | 1 | 2016 | |
| Shealy Ben | Officer | Senior Vice President Finance; Sr VP Finance & Treasurer | 6 | 2016–2018 | |
| Gilliam Richard Baxter | TenPercentOwner | 1 | 2016 | ||
| RUFFOLO ROBERT R | Director | 4 | 2017–2018 | ||
| Hornung William Karl | Officer | Chief Financial Officer | 5 | 2018–2022 | |
| Cobuzzi Robert Joseph Jr. | Director; Director,Officer; Officer | Chief Operating Officer; President & CEO | 19 | 2020–2025 | |
| Hollingsworth Jane H | Director | 14 | 2020–2026 | person page Fuzzy | |
| ELDER WILLIAM ROBERT | Officer | CFO & GC; CFO, GC & Secretary; GC & Secretary | 15 | 2020–2026 | |
| GALLOWAY CHRISTOPHER D | Officer | Chief Medical Officer | 4 | 2020–2022 | |
| Francois Eric | Director | 2 | 2021 | ||
| LANCHONEY DIANA M | Director | 4 | 2021–2023 | ||
| JAEGER RAVEN | Officer | Chief Regulatory Officer | 2 | 2022 | |
| DAVIDSON JILL | Director | 2 | 2023 | ||
| ALAM JOHN J | Director,Officer,TenPercentOwner | CEO and President; CEO & President | 12 | 2023–2026 | |
| Blackburn Kelly | Officer | EVP, Clinical Development; SVP, Clinical Development; VP, Clinical Development | 5 | 2023–2026 | |
| Gregoire Sylvie | Director,TenPercentOwner | 12 | 2023–2026 | ||
| Poulton Jeffrey V. | Director | 5 | 2023–2026 | ||
| TANNER JOHN WILLIAM | Officer | Chief Financial Officer | 4 | 2023–2024 | |
| Sabbagh Marwan | Director | 5 | 2023–2026 | ||
| ZAVRL FRANK | Director | 5 | 2023–2026 | ||
| BOGER JOSHUA S | Director; Director,TenPercentOwner | 7 | 2024–2026 | ||
| De Rosch Mark | Officer | EVP, RA and GA and PgM | 2 | 2025–2026 | |
| Winton Matthew | Officer | Chief Commercial and Business | 5 | 2025–2026 | |
| Quigley David | Director | 3 | 2025–2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2020-05-27 | Diffusion Pharmaceuticals Inc. | Pharmaceuticals | $750,001 | $750,001 | 4 | 1 |
| 2020-05-15 | Diffusion Pharmaceuticals Inc. | Pharmaceuticals | $625,000 | $625,000 | 1 | 1 |
| 2019-12-17 | Diffusion Pharmaceuticals Inc. | Pharmaceuticals | $783,348 | $783,348 | 3 | 1 |
| 2019-06-03 | Diffusion Pharmaceuticals Inc. | Pharmaceuticals | $164,132 | $164,132 | 3 | 1 |
| 2017-03-16 | Diffusion Pharmaceuticals Inc. | Pharmaceuticals | $25,000,000 | $15,830,661 | 145 | 1 |
| 2016-01-21 | Diffusion Pharmaceuticals Inc. | Pharmaceuticals | Indefinite | $85,736,378 | 181 | 1 |
| 2014-05-22 | RestorGenex Corp | Pharmaceuticals | $50,000,000 | $24,778,500 | 146 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Form D issuer | Diffusion Pharmaceuticals Inc. | VA | Form D private offerings | CIK (EXACT) |
| SEC filer | CervoMed Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Form 5500 plan sponsor | RESTORGENEX CORPORATION | EIN (EXACT) | ||
| Person page | Jane H Hollingsworth | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, MA first:
- ERGO SCIENCE CORP MA
- MILLENNIUM PHARMACEUTICALS INC MA
- ESSENTIAL THERAPEUTICS INC MA
- ARQULE INC MA
- ASCENT PEDIATRICS INC MA
- EPIX Pharmaceuticals, Inc. MA
- PRAECIS PHARMACEUTICALS INC MA
- PARATEK PHARMACEUTICALS INC MA
- PREDIX PHARMACEUTICALS HOLDINGS INC MA
- Euthymics Bioscience, Inc. MA
In other datasets, the same topic (Health) in MA:
- Nonprofit: ABBIE M GRIFFIN HOSPITAL FUND (Nonprofits (IRS Form 990))
Interests: Pharmaceutical Preparations · Health